The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
C-CAMP–Imperial College London partnership to boost biotech research, startup exchange, and translational innovation through a five-year collaboration
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The inspection is now closed, and no regulatory action has been recommended
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Subscribe To Our Newsletter & Stay Updated
